A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
Incyte Corporation
Incyte Corporation
Baylor College of Medicine
Mayo Clinic
Seagen Inc.
Pfizer
National Institutes of Health Clinical Center (CC)
Canadian Cancer Trials Group
Second Affiliated Hospital, School of Medicine, Zhejiang University
Taiho Oncology, Inc.
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Seagen Inc.
Henan Cancer Hospital
Treeline Biosciences, Inc.
Kyowa Kirin Co., Ltd.
SciTech Development, Inc.
Ohio State University Comprehensive Cancer Center
Boryung Pharmaceutical Co., Ltd
Boston Immune Technologies and Therapeutics
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Washington University School of Medicine
Tianjin Medical University Cancer Institute and Hospital
Kymera Therapeutics, Inc.
Bio-Path Holdings, Inc.
Seagen Inc.
Daiichi Sankyo
Institute of Hematology & Blood Diseases Hospital, China
Taiho Oncology, Inc.
Axter Therapeutics (Beijing) Co., Ltd
Pfizer
City of Hope Medical Center
Innate Pharma
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Wake Forest University Health Sciences
Stanford University
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Stanford University
University of Nebraska
Therapeutic Advances in Childhood Leukemia Consortium
Henan Cancer Hospital
Tessa Therapeutics
Karyopharm Therapeutics Inc
National Institutes of Health Clinical Center (CC)
Tianjin Medical University Cancer Institute and Hospital
Peter MacCallum Cancer Centre, Australia
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
TG Therapeutics, Inc.
Acrotech Biopharma Inc.
Aptevo Therapeutics